TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03995082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcome Measure Survey result feedback
Description: Patients will receive a graph of their results from the PROM survey each time they complete a survey
Study: NCT01260753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UR-63325
Description: UR-63325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate nasal spray
Description: Fluticasone propionate nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to UR 63325 and fluticasone propionate nasal spray
Study: NCT01183286

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CFFONE
Description: A password-protected, secure website, which can be accessed via a web capable cell phone. The website contains age appropriate medical and behavioral information, disease management tools and social networking features for adolescents and young people who have Cystic Fibrosis.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CF website
Description: A CF-related educational website which has some areas of CF information and services relevant to adolescents.
Study: NCT03753542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia education, booklet Providence and tele-nursing follow-up
Description: Multimedia education, booklet and weekly tele-nursing follow-up is about chemotherapy and side effects management
Study: NCT02388789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active movement
Description: same as arm description
Study: NCT03934879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FitClub
Description: Participants will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular School Activities
Description: Students will participate in regular school activities.
Study: NCT04725981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy
Description: Control group: colpotomy closure technique: 3 Z-sutures PDS 0 Intervention group: colpotomy closure technique: 3 Z sutures with PDS 0 and 1 continuous suture with V-Loc 2-0

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total laparoscopic hysterectomy
Description: Control group: colpotomy closure technique: 3 Z-sutures PDS 0 Intervention group: colpotomy closure technique: 3 Z sutures with PDS 0 and 1 continuous suture with V-Loc 2-0
Study: NCT04603248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg treatment will be given every 2 weeks up to progression or unacceptable toxicity
Study: NCT04350203

Intervention type: PROCEDURE
Intervention: Laparoscopic right colectomy with intracorporeal anastomosis (IA)
Description: First, the right colon dissection was completed by laparoscopy. An isoperistaltic side-to-side ileocolonic mechanical anastomosis was then performed by using a linear cutting stapler. The enterotomy used to enter the stapler was closed with a running suture (3-0 absorbable monofilament or a 3-0 barbed suture). Finally, the specimen was extracted through a Pfannenstiel mini-laparotomy (4-5 cm).

Intervention type: PROCEDURE
Intervention: Laparoscopic right colectomy with extracorporeal anastomosis (EA)
Description: First, the right colon was widely mobilized. A small laparotomy was performed in the mid/upper abdomen to exteriorize the colon and to perform a side-to-side mechanical anastomosis, using a linear cutting stapler (GIA). The bowel opening was closed either with a manual suture or by a second firing of the GIA.
Study: NCT00813475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal bolus insulin regimen (tight glucose control)
Description: Basal bolus insulin regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal bolus insulin regimen (standard control)
Description: basal bolus insulin regimen
Study: NCT02218996

Intervention type: OTHER
Intervention: Psychosocial treatment
Description: Regular psychosocial treatment in clinical outpatient service.
Study: NCT02243852

Intervention type: DRUG
Intervention: Growth Hormone Replacement Therapy
Description: An observational study of patients who are commencing GH replacement as part of their routine NHS clinical care to assess changes in serum FGF21 concentration and determine how these relate to changes in body composition.
Study: NCT00844883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib: given 400 mg twice per day for as long as it is beneficial

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LC Bead-TACE
Description: LC Beads loaded with doxorubicin~Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period
Study: NCT01625169

Intervention type: DRUG
Group type: OTHER
Intervention: Etravirine pharmacokinetics in breast milk and plasma
Description: HIV+ pregnant women will receive etravirine 200mg PO BID for 14 days postpartum. PK will be done on postpartum days 5 and 14.
Study: NCT03675399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supra-threshold isometric exercise
Description: The supra-threshold intensity will be stablished at 120% of participant's PFIS pre-session measurement (20% above the individual's pain threshold).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infra-threshold isometric exercise
Description: The infra-threshold intensity will be stablished at 80% of participant's PFIS pre-session measurement (20% bellow the individual's pain threshold).
Study: NCT03292484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AR101
Description: AR101
Study: NCT03390322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiaGone™
Description: Duodenal Glycemic Control™ using the DiaGone™ system
Study: NCT04099823

Intervention type: OTHER
Group type: OTHER
Intervention: MRI screening form
Description: Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urine pregnancy test
Description: Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MR brain
Description: You will be asked to lie down on the bed of the MRI scanner. Then a MRI coil/antenna will be placed over your head. This will allow us to get clearer pictures of the tissue of interest. The MRI machine makes loud knocking sounds. Because of this you will be asked to wear earplugs. You will receive a squeeze ball alarm in case you need urgent help. We will be able to talk with you and hear you during the MRI exam. The entire MRI scan will last about 45-60 minutes. The MR exam will include standard clinical images as well as the CSF flow imaging.
Study: NCT02534233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoBalloon
Description: Esophageal tissue ablation with focal freezing using nitrous oxide via a single use balloon catheter
Study: NCT06516354

Intervention type: DEVICE
Group type: OTHER
Intervention: Portable sleep apnea screening
Description: Screening of stroke and TIA patients on the stroke inpatient unit using theSTOP BANG questionnaire and portable sleep testing (PST) during inpatient hospitalization, early interpretation of PST results by neurology with prescribed treatment upon discharge from hospital
Study: NCT04230681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Patients will be randomized to one of two opioids for the treatment of post-operative pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl
Study: NCT03458520

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MR imaging
Description: undergo PET/MR imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: MR imaging
Description: Undergo MR imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT imaging
Description: Undergo PET/CT imaging
Study: NCT02127762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups.
Study: NCT01660945

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vytorin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vytorin
Study: NCT00878020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
Study: NCT01788423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid
Description: All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid
Description: All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: hearing aid
Description: All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.
Study: NCT02498652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 2.5 mg
Description: Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).~Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 2.5 mg
Description: Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).~Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg
Description: allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg
Description: allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)
Study: NCT02629705

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Carrageenan
Description: Carrageenan 250 mg bid supplemented to a standard food

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Carrageenan
Description: Carrageenan 250 mg bid supplemented to a standard food

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Placebo (Mannitol/Aerosil) bid supplemented to a standard food

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Placebo (Mannitol/Aerosil) bid supplemented to a standard food
Study: NCT03527043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10mg by mouth daily for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo control by mouth for 6 weeks
Study: NCT00133744

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Description: pills by mouth, one per day, from the first prenatal visit until delivery, 400 micrograms (mcg) folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid plus iron
Description: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplements with multiple vitamins and minerals
Description: pills, one per day, from the first prenatal visit until delivery; folic acid 400 mcg, Fe 30 mg, vitamin(vit) A 800 mcg, vit E 10 mg, vit D 5 mcg, vit C 70 mg, vit B1 1.4 mg, vit B2 1.4 mg, vit B6 1.9 mg, vit B12 2.6 mcg, Niacin 18 mg, Zn 15 mg, Cu 2mg, Iodine 150 mcg, Selenium 65 mcg
Study: NCT04398056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy and Toripalimab
Description: 1. Chemotherapy:~   The PF regimen included 5 g/m2 5-fluorouracil via a continuous intravenous infusion over 120 h and an intravenous administration of 100 mg/m2 cisplatin on day 1 for a maximum of six cycles.~2. Radiotherapy, intensity-modulated radiation therapy (IMRT), PTVnx:66-70Gy/30-33F; PTVnd:66～70Gy/30～33F; PTV1:60～64Gy/30～33F; PTV2:50～54Gy/30～33F, 5 fractions per week, for 6 weeks~3. Toripalimab 240mg every three weeks (Q3W) began on the first day of radiotherapy until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years.
Study: NCT01528696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silverlon
Description: Patients will be randomized to either receive a silver dressing. Patients who receive a silver dressing will have that dressing replaced on postoperative day number 2. This will be left in place until the patient is seen for follow up by the visiting nurse.~All patient will be evaluated by the visiting nurse on postoperative day 4 or 5 and have their wounds photographed. All patients will be contacted for a brief survey 6 weeks postpartum.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Dressing
Description: Standard island dressing. Patients who receive a standard dressing will have that dressing removed on postoperative day 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
Study: NCT04408586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine-Topiramate Extended Release
Description: Dosing of 3.75/23 mg daily for 15 days, increased to 7.5/46 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo looks exactly like the study drug, but it contains no active ingredient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online support system
Description: VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices used as part of this study. It also will allow subjects to document study medication compliance and will allow the remote visits to be conducted through a video conference between subjects and appropriate study team members.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Online support system
Description: VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices used as part of this study. It also will allow subjects to document study medication compliance and will allow the remote visits to be conducted through a video conference between subjects and appropriate study team members.
Study: NCT01348438

Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic Engager Transcatheter Aortic Valve Implantation System
Description: Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System
Study: NCT04610307

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: buffered anesthesia
Description: patients will undergo surgery under buffered local anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: buffered anesthesia
Description: patients will undergo surgery under buffered local anesthesia
Study: NCT03554590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: carbohydrate counting
Description: patients will attend a 5 meetings-structured training to learn how to manage their insulin therapy depending on the amount of carbohydrates contained in foods

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: insulin therapy according to standard care
Description: patients will not manage their insulin therapy depending on the amount of carbohydrates contained in foods, but will follow a fix basal bolus scheme
Study: NCT02448550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Study: NCT04045912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGYW-Friendly Services
Description: Drug shops will offer a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discreetly request free SRH products. Drug shops will also have an SRH product display and a tablet with SRH videos for interested customers, and drug shop employees will receive training on contraceptive counseling for AGYW.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIVST
Description: Drug shops will provide HIVST kits to AGYW for free. Employees will receive training on HIVST and will institute an HIV care referral plan for customers who require linkage to confirmatory testing or treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIVST
Description: Drug shops will provide HIVST kits to AGYW for free. Employees will receive training on HIVST and will institute an HIV care referral plan for customers who require linkage to confirmatory testing or treatment.
Study: NCT02711371

Intervention type: OTHER
Intervention: fMRI

Intervention type: OTHER
Intervention: fMRI
Study: NCT01642537

Intervention type: DEVICE
Group type: OTHER
Intervention: Rhythmia Mapping System and the Rhythmia Mapping Catheter
Description: Patients will undergo a diagnostic assessment with the Rhythmia Mapping System and the Rhythmia Mapping Catheter as part of the Electrophysiology Ablation Procedure.
Study: NCT01979744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVUS guided percutaneous coronary angioplasty with Resolute integrity stent insertion
Description: Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography guided percutaneous coronary angioplasty with Resolute integrity stent insertion
Description: Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography guided percutaneous coronary angioplasty with Promus element stent implantation
Description: Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography guided percutaneous coronary angioplasty with Promus element stent implantation
Description: Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
Study: NCT01561638

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiofrequency
Description: pulsed radiofrequency will delivered at 45V for 2 cycles of 120 seconds(temperature not more than 42degree centigrade)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Dose Radiofrequency
Description: pulsed dose pulsed radiofrequency,we will set the machine to give 480 pulses each pulse of 45 volts for 20 milliseconds duration with a temperature limit of 42 degree centigrade)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: will receive puncture for 4 minutes